New Blood Cancer Drug Helps 44% of Relapsed Patients

An investigational therapy for multiple myeloma shrank tumors in over 40% of heavily pre-treated patients, offering hope through a completely new treatment pathway.

Even better, patients get a break after one year instead of lifelong infusions.